Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q9BSI4
UPID:
TINF2_HUMAN
Alternative names:
TRF1-interacting nuclear protein 2
Alternative UPACC:
Q9BSI4; B3W5Q7; Q9H904; Q9UHC2
Background:
TERF1-interacting nuclear factor 2, also known as TRF1-interacting nuclear protein 2, plays a crucial role in telomere maintenance by being a component of the shelterin complex. This complex is essential for regulating telomere length and protection, ensuring chromosome ends are shielded from DNA damage surveillance mechanisms. Its involvement in shelterin complex assembly and potential role in tethering telomeres to the nuclear matrix highlight its significance in cellular longevity and genomic stability.
Therapeutic significance:
The protein's association with Dyskeratosis congenita, autosomal dominant, 3 and 5, diseases characterized by defective telomere maintenance leading to a spectrum of clinical manifestations, underscores its therapeutic potential. Targeting the pathways involving TERF1-interacting nuclear factor 2 could offer novel strategies for treating these complex disorders, emphasizing the importance of understanding its biological functions.